The Association for Mass Spectrometry Applications to the Clinical Lab (MSACL) 6th European meeting will take place in Salzburg, Austria later this month.

MSACL provides a forum for discussing the clinical application of mass spectrometry by bringing together academic and industrial experts in the field. The mission of MSACL is to accelerate the implementation of mass spectrometry in the clinical laboratory with the goal of contributing to the improvement of patient standard-of-care as well as reducing health care costs.

Metabolomic Diagnostic will be attending to present a poster entitled:

Evaluation of an artificial serum as a surrogate matrix for calibration samples for a preeclampsia risk prediction test

Anna Catharina Suhr, Leslie Walter Brown, Isabel Vega-Carrascal, Paloma Muñiz-Ortea, Robin Tuytten

 

A specific challenge of developing LC-MS assays for the quantification of endogenous compounds is the choice of a suitable matrix for the preparation of calibrators and QC samples. In this study, we evaluated the suitability of a substitute for plasma/serum (SeraSubTM) compared with Bovine Serum Albumin (BSA) as a surrogate matrix for the preparation of calibrators for PrePsiaTM, a screening test to predict the risk for preterm preeclampsia using LC-MS/MS*.

 

Drop by our poster (#26c on Thurs 26th from 9.30-10.30am) and talk with our Senior Scientist, Dr. Anna Suhr, to hear more about our developments.

Location: Salzburg Congress Centre, Salzburg, Austria. www.msacl.org

*This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 789083.